publicli
fund
repositori
covid
databas
right
unrestrict
research
reus
analys
form
mean
acknowledg
origin
sourc
permiss
grant
free
elsevi
long
resourc
centr
remain
activ
chest
special
featur
r
espiratori
diseas
among
lead
caus
death
major
health
threat
modern
china
develop
modern
respiratori
medicin
china
undergon
three
phase
primarili
driven
diseas
burden
correspond
regul
prioriti
fi
rst
phase
phase
prevent
manag
tb
period
pulmonari
tb
common
respiratori
diseas
china
tb
extens
studi
tb
control
one
top
prioriti
nation
public
health
program
effect
prevent
treatment
becam
avail
tb
brought
control
focu
gradual
shift
respiratori
diseas
second
phase
prevent
manag
cor
pulmonal
prevent
treatment
four
respiratori
diseas
chronic
bronchiti
emphysema
cor
pulmonal
infl
uenza
domin
fi
eld
result
special
depart
focus
respiratori
medicin
establish
gener
hospit
mani
particip
physician
becam
respiratori
specialist
period
laid
solid
foundat
develop
respiratori
medicin
china
third
phase
present
modern
respiratori
medicin
respiratori
medicin
develop
rapidli
china
respiratori
medicin
critic
care
medicin
merg
one
depart
respiratori
critic
care
medicin
mani
lead
hospit
respiratorymed
icu
past
centuri
wit
rapid
develop
respiratori
medicin
china
major
burden
respiratori
diseas
shift
infecti
diseas
chronic
noninfecti
diseas
great
achiev
made
improv
nation
standard
clinic
manag
variou
respiratori
diseas
smoke
control
specialti
respiratori
medicin
expand
pulmonari
critic
care
medicin
nevertheless
respiratori
diseas
remain
major
public
health
problem
new
challeng
air
pollut
nosocomi
infect
review
describ
histori
accomplish
new
challeng
opportun
respiratori
medicin
china
abbrevi
cap
communityacquir
pneumonia
hap
hospitalacquir
pneumonia
nippv
noninvas
posit
pressur
ventil
pah
pulmonari
arteri
hypertens
pic
pulmonari
infect
control
pte
pulmonari
thromboembol
sar
sever
acut
respiratori
syndrom
medic
commun
fi
rst
chines
guidelin
copd
manag
publish
chines
thorac
societi
chines
guidelin
gener
line
intern
guidelin
also
accommod
practic
issu
cost
avail
specifi
c
intervent
copd
list
one
major
diseas
governmentiniti
nation
project
prevent
control
noncommunic
chronic
diseas
specifi
c
goal
project
includ
earli
diagnosi
intervent
copd
smoke
control
improv
patient
selfmanag
physician
complianc
guidelin
asthma
major
clinic
problem
one
common
caus
hospit
children
china
preval
asthma
increas
preval
adult
rang
southern
china
northern
china
preval
asthma
found
higher
among
worker
chemic
factori
larg
petrochem
factori
farmer
live
rural
area
prompt
associ
asthma
environ
pollut
pathogenesi
asthma
may
also
associ
dysregul
infl
ammatori
reaction
asthma
hospitalbas
asthma
educ
manag
program
effect
improv
asthma
control
qualiti
life
chines
thorac
societi
updat
asthma
guidelin
everi
year
keep
global
initi
asthma
gina
incorpor
new
data
chines
studi
respiratori
infect
long
pose
major
health
threat
chines
peopl
tb
bacteri
pneumonia
lung
abscess
preval
lung
infect
shift
hospitalacquir
pneumonia
hap
communityacquir
pneumonia
cap
isol
antimicrobi
resist
strain
cap
hap
rais
concern
misus
antibiot
chines
guidelin
hap
cap
develop
outbreak
sever
acut
respiratori
syndrom
sar
trigger
extens
research
led
establish
effect
system
control
emerg
respiratori
viral
diseas
corticosteroid
effect
reduc
fatal
hospit
stay
critic
ill
patient
sar
vaccin
develop
prevent
experi
deal
sar
chines
medic
commun
public
health
system
respond
quickli
later
epidem
avian
establish
review
focus
recent
achiev
present
challeng
futur
direct
respiratori
medicin
china
along
rapid
develop
scienc
technolog
enhanc
intern
collabor
respiratori
medicin
china
achiev
great
progress
variou
disciplin
recent
year
mani
guidelin
manag
respiratori
diseas
develop
updat
base
intern
guidelinesconsensus
local
condit
eg
specifi
c
physiolog
condit
region
econom
situat
estim
peopl
older
year
million
peopl
suffer
copd
china
copd
impos
huge
econom
burden
china
cost
care
patient
copd
equival
annual
incom
rural
resid
urban
resid
effort
made
identifi
risk
factor
mechan
copd
develop
china
smoke
air
pollut
biomass
fuel
use
occup
dust
exposur
seem
account
high
copd
preval
male
sex
low
socioeconom
statu
also
associ
copd
sever
genet
factor
polymorph
tumor
necrosi
factora
aquaporin
heme
epoxid
shown
increas
suscept
copd
chines
popul
causal
relationship
depress
copd
exacerb
also
propos
ongo
hot
research
topic
also
includ
role
infl
ammat
copd
therapeut
intervent
aim
prevent
destruct
lung
tissu
clinic
manag
copd
exacerb
reduc
carbocistein
theophyllin
salmeterolfl
uticason
propion
communitybas
intervent
includ
health
educ
individu
treatment
pulmonari
rehabilit
may
effect
prevent
manag
copd
although
data
older
peopl
abund
preval
copd
younger
popul
known
younger
patient
particularli
target
sinc
copd
may
start
earli
life
earli
diagnosi
intervent
may
reduc
progress
achiev
goal
nationwid
survey
lung
function
recent
initi
china
begin
peopl
year
age
battl
copd
china
arduou
task
requir
joint
effort
govern
death
diseas
predict
year
similar
develop
countri
lung
cancer
case
inoper
diagnosi
although
highqual
care
becom
avail
resid
socioeconom
develop
area
treatment
lung
cancer
remain
primit
mani
rural
area
probabl
uniqu
china
respiratori
physician
involv
diagnosi
well
manag
lung
cancer
includ
administr
chemotherapi
although
chines
guidelin
wide
avail
heterogen
qualiti
care
among
center
especi
dispar
urban
rural
area
restrict
manag
lung
cancer
consist
way
elsewher
around
globe
platinumbas
doublet
chemotherapi
remain
commonli
use
regimen
new
epiderm
growth
factor
receptortarget
therapi
also
investig
mani
medic
center
recent
year
increasingli
region
hospit
equip
ct
scanner
even
petct
scanner
facilit
earli
diagnosi
lung
cancer
multidisciplinari
treatment
especi
molecular
target
therapi
improv
surviv
patient
lung
cancer
pulmonari
thromboembol
pte
significantli
underdiagnos
china
long
time
late
sever
clinic
studi
demonstr
fact
common
diseas
chines
popul
fi
rst
guidelin
pte
publish
fi
rst
nation
confer
pte
held
nationwid
collabor
group
organ
china
group
conduct
seri
multicent
studi
pte
effect
increas
awar
improv
diagnosi
manag
pte
lead
decreas
pte
fatal
china
genet
polymorph
associ
pte
among
chines
character
sever
genet
trait
fibrinogen
b
plasminogen
activ
link
increas
risk
pte
chines
popul
howev
low
incid
factor
v
leiden
prothrombin
gene
methylenetetrahydrofol
reductas
gene
muta
tion
suggest
major
genet
risk
factor
pte
chines
popul
great
effort
made
fi
nd
optim
regimen
treat
pte
wang
et
al
demonstr
short
regimen
urokinas
iv
show
similar
effi
caci
safeti
standard
urokinas
iv
treat
acut
pulmonari
embol
new
regimen
signifi
cantli
reduc
cost
treatment
anoth
multicent
trial
group
report
similar
effi
caci
better
safeti
dose
infl
uenza
clinic
featur
incu
bation
period
common
symptom
report
effi
caci
safeti
oseltamivir
maxingshiganyinqiaosan
formula
tradit
chines
medicin
treat
infl
uenza
test
studi
effect
tradit
chines
drug
especi
import
drug
wide
accept
chines
peopl
appli
thousand
year
rapid
success
control
pandem
china
highli
prais
sar
epidem
brought
control
chines
govern
implement
seri
measur
strengthen
public
health
system
reinforc
effort
tb
control
increas
input
tb
control
china
achiev
major
goal
fi
ght
tb
howev
tb
control
china
remain
longterm
public
health
challeng
high
rate
multidrug
resist
emerg
tb
hiv
coinfect
forese
futur
advanc
dna
sequenc
genom
technolog
allow
rapid
identifi
cation
new
pathogen
facilit
studi
genegen
geneenviron
interact
specifi
c
diseas
condit
studi
interact
lung
microbiom
microbi
popul
locat
organssystem
interstiti
lung
diseas
increasingli
recogn
china
sarcoidosi
studi
interstiti
lung
diseas
hladr
gene
may
associ
suscept
sarcoidosi
chines
popul
glucocorticoid
therapi
may
improv
outcom
idiopath
pulmonari
fi
brosi
also
common
condit
china
lung
transplant
may
feasibl
patient
endstag
idiopath
pulmonari
fi
brosi
occup
lung
diseas
character
high
morbid
mortal
larg
proport
chines
peopl
high
risk
diseas
pneumoconios
major
occup
lung
diseas
account
total
occup
diseas
new
case
report
annual
exposur
chrysotil
asbesto
arsen
radon
cadmium
induc
pneumoconiosi
furthermor
higher
incid
lung
cancer
observ
patient
silicosi
underli
pathogenesi
investig
substanti
proport
cancerrel
death
china
attribut
lung
cancer
china
new
lung
cancer
case
estim
rang
chines
popul
year
old
close
associ
obstruct
sleep
apnea
syndrom
cardiovascular
diseas
describ
sleep
breath
disord
assembl
chines
thorac
societi
organ
fi
rst
guidelin
sleep
breath
disord
issu
updat
sleep
laboratori
establish
throughout
china
almost
univers
hospit
hospit
provinc
level
establish
sleep
laboratori
laboratori
oper
depart
eg
ear
nose
throat
depart
sleep
medicin
china
still
infanc
awar
sleep
breath
disord
remain
promot
among
primari
healthcar
provid
insur
coverag
diagnosi
treatment
sleep
disord
key
wide
public
benefi
world
largest
cigarett
consum
manufactur
china
million
smoker
million
nonsmok
expos
secondhand
smoke
estim
million
chines
peopl
die
smokingrel
diseas
year
direct
econom
burden
tobacco
use
reach
billion
yuan
equival
billion
us
dollar
china
huge
impact
tobacco
use
smoke
control
becom
top
prioriti
chines
health
author
sinc
ratifi
cation
framework
convent
tobacco
control
event
consid
world
health
organ
mileston
diseas
prevent
control
china
despit
progress
enforc
smokingrel
law
regul
remain
challeng
task
exist
public
health
polici
strengthen
new
strategi
includ
rais
tax
tobacco
product
explor
physician
play
lead
role
smoke
control
smoke
cessat
train
program
physician
especi
male
physician
less
like
provid
smoke
cessat
counsel
patient
enforc
research
smoke
hazard
smoke
control
gradual
becom
highli
special
area
medicin
includ
elucid
smoke
preval
social
behavior
harm
ingredi
tobacco
smokingrel
diseas
recombin
tissuetyp
plasminogen
activ
decreas
mg
mg
treat
acut
massiv
pte
current
clinic
trial
new
anticoagul
pte
thrombolyt
therapi
submass
pulmonari
embol
initi
improv
diagnosi
pte
patient
chronic
thromboembol
pulmonari
hypertens
associ
pulmonari
arteri
hypertens
pah
identifi
ed
fi
medic
center
china
provid
pulmonari
endarterectomi
lungheart
transplant
current
registri
pah
multicent
trial
evalu
target
therapi
pah
chines
popul
progress
laboratori
research
pulmonari
hypertens
focus
effect
vanilloidrel
ion
channel
ca
ion
prolifer
human
pulmonari
arteri
smooth
muscl
cell
conduct
chines
investig
china
clinic
applic
posit
pressur
ventil
date
back
use
noninvas
posit
ventil
start
chines
thorac
societi
develop
guidelin
recommend
mechan
ventil
noninvas
posit
pressur
ventil
nippv
concept
pulmonari
infect
control
pic
window
propos
facilit
transit
invas
noninvas
ventil
copd
exacerb
pic
window
denot
manag
ventil
support
patient
copd
acut
respiratori
failur
trigger
pulmonari
infect
earli
extub
follow
noninvas
mechan
ventil
time
pic
window
signifi
cantli
reduc
risk
ventilatoracquir
pneumonia
improv
prognosi
pic
window
subsequ
proven
use
replac
intub
sequenti
noninvas
ventil
nationwid
multicent
prospect
random
control
trial
anoth
multicent
random
control
trial
show
earli
use
nippv
acut
exacerb
copd
could
allevi
respiratori
muscl
fatigu
prevent
worsen
respiratori
failur
applic
nippv
also
shown
benefi
cial
sever
hypercapn
encephalopathi
acut
lung
injuri
multicent
random
control
clinic
trial
larger
sampl
size
conduct
china
assess
benefi
nippv
use
patient
acut
lung
injuri
link
sleep
apnea
respiratori
diseas
increasingli
recogn
china
preval
obstruct
sleep
apnea
syndrom
medicin
critic
care
medicin
current
nation
standard
curricula
certifi
cation
examin
avail
fi
eld
reform
medic
educ
train
urgent
need
continu
medic
educ
program
care
design
provid
meet
rapidli
increas
demand
respiratori
diseas
lead
caus
death
socioeconom
burden
china
signifi
cant
progress
made
improv
manag
variou
respiratori
diseas
tobacco
control
respiratori
diseas
remain
major
public
health
problem
wherea
respiratori
medicin
face
new
challeng
battl
respiratori
diseas
chines
thorac
societi
take
lead
role
promot
collabor
effort
improv
standard
medic
practic
patient
care
support
research
train
young
respiratori
physician
ultim
fulfi
mission
save
live
allevi
suffer
patient
respiratori
diseas
mechan
tobacco
cessat
manag
tobacco
depend
smoke
prevent
control
like
emerg
develop
occup
medicin
practic
prevent
manag
occup
diseas
special
medic
disciplin
tobacco
medicin
grow
popular
respiratori
medicin
face
signifi
cant
challeng
overcom
obstacl
need
continu
improv
understand
complex
respiratori
diseas
develop
effect
therapi
prevent
treat
condit
rapid
develop
scienc
technolog
offer
new
approach
achiev
goal
advanc
biomed
scienc
enabl
us
understand
lung
diseas
molecular
level
modern
medicin
empow
develop
multipl
approach
pharmaceut
therapi
cell
therapi
bioengin
devic
treat
respiratori
diseas
pulmonari
physician
need
integr
divers
area
basic
scienc
clinic
research
conduct
translat
research
promot
inform
exchang
bench
bedsid
advanc
knowledg
basic
clinic
scienc
encourag
formul
challeng
question
base
bedsid
observ
elucid
fundament
molecular
cellular
mechan
diseas
process
use
current
scienc
knowledg
technolog
also
translat
scientifi
c
discoveri
basic
research
clinic
applic
new
improv
therapeut
strategi
develop
base
biolog
foundat
effect
nation
program
respiratori
diseas
control
urgent
need
welldesign
nationwid
epidemiolog
studi
preval
morbid
mani
respiratori
diseas
carri
evalu
present
futur
diseas
burden
studi
genet
suscept
respiratori
diseas
among
chines
popul
enforc
improv
earli
diagnosi
intervent
integr
clinic
resourc
multicent
research
push
forward
improv
diagnosi
treatment
communitybas
comprehens
intervent
implement
ensur
avail
medic
resourc
essenti
drug
equip
human
resourc
prioriti
futur
direct
also
includ
organ
largescal
clinic
trial
develop
updat
guidelin
respiratori
diseas
final
shortag
respiratori
physician
remain
challeng
problem
limit
number
teach
hospit
offer
effect
train
respiratori
